VJHemOnc is committed to improving our service to you

ASH 2019 | Durable responses to ibrutinib and venetoclax in R/R MCL: 3-year AIM update

VJHemOnc is committed to improving our service to you

Sasanka Handunnetti

Sasanka Handunnetti, MBBS, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, outlines the rationale and results of the AIM trial (NCT02471391), investigating the combination of ibrutinib and venetoclax in relapsed/refractory mantle cell lymphoma (MCL). Results from this three-year update are promising and demonstrate that ibrutinib in combination with venetoclax offers durable responses to patients who otherwise have limited durable therapeutic options. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter